Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(100.0%)
4Total
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01205347Phase 4Completed

Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction

Role: lead

NCT00906451Phase 4Completed

Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

Role: lead

NCT00905905Phase 4Completed

Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction

Role: lead

NCT01061450Phase 4Completed

Simvastatin and Diastolic Dysfunction

Role: lead

All 4 trials loaded